36 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
15 Mar 22
Cogent Biosciences Provides Corporate Updates, Fourth Quarter
8:08am
.
Appointed Lora Marden as Vice President, Patient Advocacy, Engagement and Innovation
Ms. Marden joins with over 15 years of rare disease … biopharmaceutical and social services experience. Prior to joining Cogent, Ms. Marden was the Head of Global Patient Advocacy & Engagement at Kiniksa
8-K
EX-99.1
COGT
Cogent Biosciences Inc
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am
/Y, while sparing wild type EGFR target engagement.
Upcoming Milestones
Present updated clinical data from APEX, a global, multicenter Phase 2
8-K
EX-99.1
COGT
Cogent Biosciences Inc
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
inhibitor demonstrated high clinical target engagement without metabolic dysfunction commonly associated with molecules in the class
In November 2023
8-K
EX-99.1
COGT
Cogent Biosciences Inc
30 Nov 20
Other Events
5:06pm
Clinical Studies Pre-clinical KIT selectivity and potency along with clinical experience – safety + target engagement Phase 2 start as single agent … Studies Pre-clinical KIT selectivity and potency along with clinical experience – safety + target engagement Phase 2 start as single agent in Phase 2 start
8-K
EX-10.2
ptw5jqesjejcc9jhsj
26 Oct 20
Cogent Biosciences Appoints
7:13am
DEFM14A
m1kfucgpvx
9 Oct 20
Proxy related to merger
4:44pm
8-K
EX-10.1
bxv zpp6w
27 Dec 21
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.3
69wp3h ca
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am
8-K
EX-10.2
qgmzjv11sa6h8nzggs5
27 Dec 21
Departure of Directors or Certain Officers
4:05pm